ABIVAX Société Anonyme (ABVX) Stock Price & Analysis
ABIVAX Société Anonyme (ABVX) closed at USD 90.23 on Thursday, October 22, 2026, down 3.49% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 93.49; the Oct 22, 2026 session ranged USD 88.15–93.98 on volume of 895,411 shares. Market capitalization is $7.87B, with a 52-week range of USD 69.81–148.83 (NGM). Source: Nexqual, retrieved October 23, 2026 at 09:12 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ABVX.md
Key facts (ABVX)
- 1 of 80 tracked superinvestors hold ABVX (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 1.67 on a 1–5 scale) (12 analysts), mean target USD 163.58 (range 142–181).
- Total return with dividends: 1Y -0.3% vs S&P 500 +14.9%; 5Y +987.1% vs S&P 500 +80.3%.
- Next earnings: 2026-09-21, EPS estimate USD -0.86, revenue estimate $676K.
Superinvestors (SEC 13F-HR, Q2 2026) (ABVX)
1 of 80 tracked investors hold ABVX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Lee Ainslie | Maverick Capital | 0.05% | $5.3M | New position |
Analysts (ABVX)
Consensus Buy (mean 1.67 on a 1–5 scale), 12 analysts; mean target USD 163.58 (low 142, high 181).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | Wedbush | Target lowered | Neutral | $118 → $96 |
| 2026-10-20 | Guggenheim | Reiterated | Buy | $175 |
| 2026-09-22 | Truist Securities | Target lowered | Buy | $155 → $151 |
| 2026-09-22 | Wedbush | Target lowered | Neutral | $140 → $118 |
| 2026-09-22 | Barclays | Maintained | Overweight | $148 |
| 2026-09-10 | Goldman Sachs | Initiated | Buy | $155 |
| 2026-09-05 | BTIG | Reiterated | Buy | $175 |
| 2026-07-09 | Piper Sandler | Target raised | Overweight | $165 → $175 |
| 2026-07-02 | Truist Securities | Target raised | Buy | $135 → $155 |
| 2026-07-01 | Citizens | Reiterated | Market Outperform | $187 |
| 2026-06-30 | Jefferies | Upgrade | Hold → Buy | $108 → $158 |
| 2026-06-30 | Leerink Partners | Target raised | Outperform | $140 → $148 |
Total return (dividends reinvested) (ABVX)
| 1Y (from 2025-10-23) | 5Y (from 2023-10-16) | |
|---|---|---|
| Total return | -0.3% | +987.1% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -0.3% | +120.4% |
| Volatility (annualized) | 91.1% | 127.8% |
| Max drawdown | -50.1% (Dec 2025→Jun 2026) | -66.3% (Apr 2024→Mar 2025) |
ABVX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.86 | $-0.67 | +27.4% | $676,440 | 4 |
| Next quarter (ends Dec 2026) | $-0.89 | $-0.77 | +15.9% | $686,030 | 4 |
| Current fiscal year (ends Dec 2026) | $-4.17 | $-3.62 | +15.1% | $4.0M | 7 |
| Next fiscal year (ends Dec 2027) | $-3.84 | $-3.24 | +18.5% | $71.9M | 7 |
ABVX options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 7 | 68.0% | ±8.1% |
| Nov 6, 2026 | 14 | 59.2% | ±9.6% |
| Nov 13, 2026 | 21 | 65.1% | ±12.8% |
| Nov 20, 2026 | 28 | 62.2% | ±14.0% |
| Nov 27, 2026 | 35 | 64.3% | ±16.1% |
| Dec 4, 2026 | 42 | 63.0% | ±17.2% |
| Dec 18, 2026 | 56 | 65.8% | ±20.7% |
| Jan 15, 2027 | 84 | 63.5% | ±24.3% |
30-day implied volatility 60.7% vs 54.1% realized over the last 30 trading days. Put/call ratio (volume) 0.38. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:12 UTC)
| Price | USD 90.23 |
|---|---|
| Change | ▼ 3.49% (down) |
| Previous Close | USD 93.49 |
| Open | USD 92.29 |
| Day Range | USD 88.15 – 93.98 |
| 52-Week Range | USD 69.81 – 148.83 |
| Volume | 895,411 shares |
| Market Cap | $7.87B |
| Exchange | NGM |
Technical Analysis (ABVX)
Nexqual's technical model rates ABVX "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:12 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 41.67 (neutral) |
| vs SMA50 | Below (USD 103.97) |
| MACD | -3.91 (negative) |
Analyst Ratings (ABVX)
Wall Street analysts rate ABVX "Buy" based on 12 analysts, with a mean price target of USD 163.58 (range USD 142–181), per Nexqual as of October 23, 2026 at 09:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 163.58 |
| High Target | USD 181 |
| Low Target | USD 142 |
| Buy / Hold / Sell | 12 / 0 / 0 |
Earnings (ABVX)
| Next Earnings Date | 2026-09-21 |
|---|---|
| EPS Estimate | USD -0.86 |
| Revenue Estimate | $676,440 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.69 vs est -0.86 ▼ miss |
| 2026-03-31 | USD -0.71 vs est -0.81 ▲ beat |
| 2025-12-31 | USD -1.18 vs est -1.05 ▼ miss |
| 2025-09-30 | USD -2.47 vs est -0.79 ▼ miss |
Source: Nexqual, October 23, 2026 at 09:12 UTC.
Financials & Fundamentals (ABVX)
| Total Revenue | $4.67M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -6.80% |
| Gross Margin | +100.00% |
| Operating Margin | -8617.93% |
| Profit Margin | +0.00% |
| ROE | -252.35% |
| Debt / Equity | 0 |
| Current Ratio | 5.97 |
| Total Cash | $402.38M |
| Total Debt | $1.21M |
Source: Nexqual, October 23, 2026 at 09:12 UTC.
Financial Health Score (ABVX)
Nexqual rates ABIVAX Société Anonyme's overall financial health "Weak" across five dimensions, as of October 23, 2026 at 09:12 UTC.
| Growth | Critical — Revenue -63% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — EUR 402M cash vs EUR 1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -EUR 197M (TTM) |
| Efficiency | Critical — ROE -252%, ROA -62.9% |
Ownership (ABVX)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +72.25% |
| Shares Outstanding | 87.27M |
| Float | 65.02M |
| Short % of Float | +9.02% |
Source: Nexqual, October 23, 2026 at 09:12 UTC.
Leadership (ABVX)
ABIVAX Société Anonyme is led by Marc M. P. de Garidel, CEO & Director, per Nexqual as of October 23, 2026 at 09:12 UTC.
| CEO & Director | Marc M. P. de Garidel |
|---|---|
| EVP, CFO & Board Secretary | Didier Blondel |
Major Backers & Investors (ABVX)
Notable institutional backers of ABIVAX Société Anonyme include TCG Crossover Management, LLC, Darwin Global Management, Ltd., Helikon Investments Ltd, according to Nexqual as of October 23, 2026 at 09:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| TCG Crossover Management, LLC | 6.86% |
| Darwin Global Management, Ltd. | 4.14% |
| Helikon Investments Ltd | 3.18% |
| Vestal Point Capital, LP | 2.68% |
| Jupiter Topco LLC | 2.19% |
| UBS Group AG | 2.11% |
| Adar1 Capital Management, LLC | 2.06% |
| Caligan Partners, LP | 1.78% |
Source: Nexqual, October 23, 2026 at 09:12 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TGTX | TG Therapeutics, Inc. | USD 53.16 | ▼ 0.08% |
| AXSM | Axsome Therapeutics, Inc. | USD 156.07 | ▼ 0.15% |
| ARWR | Arrowhead Pharmaceuticals, Inc. | USD 58.36 | ▼ 0.82% |
| SYRE | Spyre Therapeutics, Inc. | USD 92.33 | ▼ 0.67% |
| CYTK | Cytokinetics, Incorporated | USD 62.33 | ▼ 0.84% |
| PTGX | Protagonist Therapeutics, Inc. | USD 139.53 | ▲ 1.05% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:12 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt